Royalty Pharma Announces Inaugural Investor Day
February 16, 2022 08:15 ET
|
RP Management, LLC
NEW YORK, Feb. 16, 2022 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will host an inaugural Investor Day in New York City on Tuesday, May 17, 2022, starting at 8:30...
Royalty Pharma Reports Q4 and Full Year 2021 Results
February 15, 2022 07:00 ET
|
RP Management, LLC
Net cash provided by operating activities (GAAP) of $490 million; Adjusted Cash Receipts(1) (non-GAAP) of $543 million and Adjusted Cash Flow(2) (non-GAAP) of $488 millionAnnounced transactions of up...
Royalty Pharma to Announce Fourth-Quarter and Full-Year 2021 Financial Results on February 15, 2022
January 20, 2022 07:45 ET
|
RP Management, LLC
NEW YORK, Jan. 20, 2022 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its fourth-quarter and full-year 2021 financial results on Tuesday, February 15,...
Royalty Pharma Highlights Accomplishments and Provides Business Update at 40th Annual J.P. Morgan Healthcare Conference
January 10, 2022 07:00 ET
|
RP Management, LLC
2021 Net cash provided by operating activities (GAAP) expected to be in the range of $2,010 to $2,030 million; 2021 Adjusted Cash Receipts (non-GAAP) expected to be at high end of guidance range of...
Royalty Pharma and Cytokinetics Announce Funding Agreements Totaling up to $450 Million
January 07, 2022 08:07 ET
|
RP Management, LLC
Royalty Pharma Extends Capital to Cytokinetics to Support the Commercial Launch of Omecamtiv Mecarbil and the Further Development of AficamtenRoyalty Pharma Purchases Royalties on Future Sales of...
Royalty Pharma Announces 12% Dividend Increase
January 06, 2022 08:30 ET
|
RP Management, LLC
NEW YORK, Jan. 06, 2022 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that its board of directors has declared a dividend for the first quarter of 2022 of $0.19 per Class A...
Royalty Pharma to Present at the J.P. Morgan Healthcare Conference on January 10
January 05, 2022 16:15 ET
|
RP Management, LLC
NEW YORK, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will present at the 40th Annual J.P. Morgan Healthcare Conference on Monday, January 10, 2022 at...
Royalty Pharma to Present at Evercore ISI 4th Annual HealthCONx Virtual Conference
November 29, 2021 16:15 ET
|
RP Management, LLC
NEW YORK, Nov. 29, 2021 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it is scheduled to participate in a fireside chat at the Evercore ISI 4th Annual HealthCONx Virtual...
Royalty Pharma Acquires Additional Royalty Interests in BCX9930 and ORLADEYO from BioCryst Pharmaceuticals
November 22, 2021 07:10 ET
|
RP Management, LLC
Provides funding for BCX9930/oral Factor D program across multiple indicationsAgreements supported by strength of ORLADEYO® (berotralstat) launch and confidence in future opportunity NEW YORK and...
Royalty Pharma Reports Third Quarter 2021 Results
November 10, 2021 07:00 ET
|
RP Management, LLC
Net cash provided from operating activities (GAAP) of $470 million; Adjusted Cash Receipts(1) (non-GAAP) of $587 million and Adjusted Cash Flow(2) (non-GAAP) of $441 millionAnnounced transactions of...